Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genscript Biotech ( (HK:1548) ) just unveiled an announcement.
Genscript Biotech has announced that its associate, Legend Biotech Corporation, has filed its fourth-quarter and full-year 2025 financial results and recent business highlights with the U.S. Securities and Exchange Commission via a Form 6-K. The company emphasized that these financial figures relate solely to Legend and not to Genscript itself, and urged shareholders and potential investors to remain mindful of investment risks and exercise caution when trading Genscript’s securities.
The disclosure underscores Genscript’s role as a significant stakeholder in a Nasdaq-listed biotech peer and provides investors with indirect insight into the performance of its associate. However, Genscript made clear that no inference should be drawn about its own financial condition from Legend’s results, reinforcing the need for investors to distinguish between the two entities when making investment decisions.
The most recent analyst rating on (HK:1548) stock is a Sell with a HK$13.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation is a Cayman Islands–incorporated biotechnology company listed in Hong Kong, with business interests that include an equity stake in Nasdaq-listed Legend Biotech Corporation. Legend operates as an associate of Genscript, reflecting Genscript’s exposure to global biopharmaceutical markets through this U.S.-listed affiliate.
Average Trading Volume: 8,618,525
Technical Sentiment Signal: Sell
Current Market Cap: HK$25.41B
Find detailed analytics on 1548 stock on TipRanks’ Stock Analysis page.